Trump unveils deals to lower prices of weight loss drugs DW 11/07/2025
The Trump administration secured discounts from Eli Lilly and Novo Nordisk for GLP-1 weight-loss drugs in exchange for tariff relief to reduce US drug costs.
GLP-1 obesity and diabetes drugs produced massive profits for Novo Nordisk and Eli Lilly, funding factory expansions while political moves threaten steep price cuts.